Madrigal Pharmaceuticals, Inc. (MDGL) Financials
MDGL Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 640.5 million | 235.2 million |
2023-09-30 | 238.0 million | 215.7 million |
2023-06-30 | 302.5 million | 199.0 million |
2023-03-31 | 332.4 million | 182.3 million |
MDGL Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -81.0 million | 14.9 million |
2023-09-30 | -85.3 million | 12.7 million |
2023-06-30 | -75.4 million | 11.0 million |
2023-03-31 | -84.1 million | 11.3 million |
MDGL Net Income
No data available :(
MDGL Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 634.1 million | - | 1.7 million |
2023-09-30 | 232.4 million | - | 1.8 million |
2023-06-30 | 298.4 million | - | 411000 |
2023-03-31 | 329.5 million | 84.0 million | 653000 |
MDGL Shares Outstanding
MDGL Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 1.0 million | 70.5 million | 46.5 million | - |
2023-09-30 | 339000 | 71.0 million | 27.6 million | - |
2023-06-30 | 69000 | 68.6 million | 17.8 million | - |
2023-03-31 | 35000 | 62.2 million | 16.2 million | - |
MDGL Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | - | 142000 |
2023-09-30 | - | 135000 |
2023-06-30 | - | 126000 |
2023-03-31 | - | 124000 |
MDGL
Price: $229.84
52 week price:
Earnings Per Share: -19.99 USD
P/E Ratio: -8.90
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 132314
Ebitda: -8.4 millionMarket Capitalization: 5.0 billion